NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. ...

Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

Good day and welcome to the Vertex Pharmaceuticals third-quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

FSGS presents significant management challenges, with nephrologists (n=102) estimating that, on average, nearly half of their patients are not optimally managed with existing therapies. Spherix’s ...

Gordon Technologies LLC ("Gordon"), an Enersol company, has acquired Vertex Downhole Trading LLC ("Vertex UAE"), which is the Eastern Hemisphere business of Vertex Downhole Technologies Inc, based in ...

Analyst Whitney Ijem from Canaccord Genuity maintained a Sell rating on Vertex Pharmaceuticals (VRTX – Research Report) and decreased the ...

The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) ...

First up, Vertex Pharmaceuticals Incorporated (VRTX ... The data featured their investigational oral pain signal inhibitor for treating moderate-to-severe acute pain. The research included ...

It claims to have proprietary linkers that stay stable for longer, ensuring the payload they’re attached to — a commonly used ADC toxin called a topoisomerase inhibitor — is precisely ... much like it ...